ArticleBMC public health2025
The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal Trends and Model-Based Projections of Female-Specific Cancer Burden Among East Asian Women Aged 55 Years and Older: A GBD 2023 Analysis.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papillomavirus (HPV)-related diseases have risen in Japan since recommendations for the HPV vaccine were suspended in 2013. This study evaluated the public health benefit of extending the current 3-year nonavalent HPV (9vHPV) catch-up vaccination program for females 17-26 years of age to 6 years.
methodsA dynamic transmission model calibrated to Japanese specific demographic and epidemiological data compared the impact of different 9vHPV vaccination scenarios on female and male HPV-related diseases over a 100-year time horizon. The base-case analysis compared the routine vaccination in combination with the current 3-year catch-up program for females 17-26 years of age from 2022 to 2025 (status quo) to the routine vaccination in combination with an extended 6-year program from 2022 to 2028 (6-year catch-up scenario) for Japan.
resultsHPV-related disease incidence with the 6-year catch-up scenario decreased further than the status quo over 100 years. Extending catch-up vaccinations from three to six years in combination with routine vaccination prevented an additional 413,454 HPV-related disease cases and 7,184 deaths for both sexes. Anogenital warts had the highest number of averted cases (361,020 cases) and males (229,867 cases) had more total HPV-related disease cases averted than females (183,586 cases).
conclusionsRoutine vaccination in combination with an extension of the catch-up HPV vaccination strategy for females 17-26 years of age from three to six years may expedite the decrease of morbidity and mortality due to HPV-related diseases in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.